Imatinib Mesylate Tablet, Film Coated
Product Images NDC 51407-270

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Imatinib Mesylate (NDC 51407-270). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Golden State Medical Supply, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

51407-269-90lb Imatinib Mesylate 100 mg Tab.jpg (51407 269 90lb Imatinib Mesylate 100 mg Tab)

The text describes a medication with the NDC code 51407-269-90, called Imatinib Mesylate. The medication is in the form of tablets and is available in a pack of 90. The dosage information can be found in the package insert. The medication must be stored at a temperature range of 20° to 25°C (68° to 77°F) and protected from moisture. It should be kept out of reach of children and closed with a child-resistant closure. The medication is manufactured by Mylan LLC, Caguas PR, 00726, and packaged by GSMS, Incorporated, Camarilio, CA 83012 USA.*

FDA Label Image

51407-270-30lb Imatinib Mesylate 100 mg Tab.jpg (51407 270 30lb Imatinib Mesylate 100 mg Tab)

NDC 51407-270-30 is a pack of Imatinib Mesylate Tablets containing 400mg of imatinib per each film-coated tablet manufactured by Mylsn LLC in Caguas PR, 00725 and Packaged by GSMS, Incorporated in Camarilio, CA 83012 USA. The tablets should be stored in a tight, light-resistant container at a temperature between 20 to 26°C and protected from moisture. The pack includes further details about the dosage and usage.*

FDA Label Image

Imatinib Structural Formula (Image 01)

FDA Label Image

Figure 1: Progression Free Survival (itt Principle) (Image 04)

This text appears to describe a study involving patients, with some data presented in a table format. Unfortunately, the text is incomplete and some characters are missing, making it difficult to fully understand the purpose and results of the study. However, it does appear to include information about patients with "progression" and "censorship" or discontinuation, as well as hazard ratios and a statistical test. Without more complete information, it is not possible to provide a useful description beyond this.*

FDA Label Image

Figure 2: Time To Progression To Ap Or Bc (itt Principle) (Image 05)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.